Clinical Trial

Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated May 20, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The study will evaluate the pharmacokinetic characteristics, safety, tolerability, and preliminary efficacy of 9MW1911 in combination with standard of care COPD maintenance therapy in patients with moderate to severe COPD.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-14.
Status change: Recruiting → Active, Not Recruiting 2025-05-15
Trial Details
NCT Number NCT06175351
Lead Sponsor Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Enrollment 80 participants
Start Date 2023-07-06
Primary Completion 2025-09-30 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-20